Insights
More Articles
- Study shows low-cost arthritis drug's efficacy in blood cancers
- EU OKs Abbott's mechanical heart valve, occluder
- AstraZeneca gets Chinese marketing rights for IBS treatment Linzess
- Study shows efficacy of dapagliflozin in HF with, without diabetes
- NIH awards $4.6M grant for Inovio's antimicrobial resistance research
Study shows low-cost arthritis drug's efficacy in blood cancers
A small British study evaluated data from 11 patients with polycythemia vera and essential thrombocythemia using the rheumatoid arthritis drug methotrexate and found that the drug improved their disease symptoms and also lowered raised blood counts, according to the British Journal of Haematology. "Given the very low cost of MTX, this research could offer an effective therapy on a budget accessible to healthcare systems throughout the world -- marking a potentially substantial clinical and health economic benefit," said study co-author Dr. Martin Zeidler of the UK's University of Sheffield. BreakingNews (Ireland) (9/17)